Literature DB >> 17686054

Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells.

Kyu-Tae Kim1, Kristin Baird, Sean Davis, Obdulio Piloto, Mark Levis, Li Li, Peili Chen, Paul Meltzer, Donald Small.   

Abstract

Constitutively activating internal tandem duplication (ITD) mutations of the receptor tyrosine kinase FLT3 (Fms-like tyrosine kinase 3) play an important role in leukaemogenesis. We have examined, by cDNA microarray analysis, the changes in gene expression induced by FLT3/ITD or constitutively activated wild type FLT3 signalling. A limited set of genes was consistently affected by FLT3 inhibition. In confirmation of their FLT3 dependence, these genes returned toward pretreatment levels of expression after reversal of FLT3 inhibition. Several of the most significantly affected genes are involved in the RAS/mitogen-activated protein kinase, Janus kinase/signal transducer and activator of transcription and phosphatidylinositol 3 kinase (PI3K)/AKT pathways. These data suggest that constitutively activated FLT3 works through multiple signal transduction pathways. PIM1, MYC and CCND3 were chosen from this gene set to explore their biological roles. Knock-down of these genes by small interfering RNA showed that these genes play important roles in constitutively activated FLT3 expressing cells. The alterations of the gene expression profiles in these cells help to further elucidate the mechanisms of FLT3-mediated leukaemogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17686054     DOI: 10.1111/j.1365-2141.2007.06696.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

1.  c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.

Authors:  Nidal Muvarak; Shannon Kelley; Carine Robert; Maria R Baer; Danilo Perrotti; Carlo Gambacorti-Passerini; Curt Civin; Kara Scheibner; Feyruz V Rassool
Journal:  Mol Cancer Res       Date:  2015-03-31       Impact factor: 5.852

2.  MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.

Authors:  Jeng-Wei Lu; Yu-Min Lin; Yen-Ling Lai; Chien-Yuan Chen; Chung-Yi Hu; Hwei-Fang Tien; Da-Liang Ou; Liang-In Lin
Journal:  Med Oncol       Date:  2015-06-19       Impact factor: 3.064

3.  Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model.

Authors:  Sarah Greenblatt; Li Li; Christopher Slape; Bao Nguyen; Rachel Novak; Amy Duffield; David Huso; Stephen Desiderio; Michael J Borowitz; Peter Aplan; Donald Small
Journal:  Blood       Date:  2012-02-08       Impact factor: 22.113

4.  AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.

Authors:  Erika K Keeton; Kristen McEachern; Keith S Dillman; Sangeetha Palakurthi; Yichen Cao; Michael R Grondine; Surinder Kaur; Suping Wang; Yuching Chen; Allan Wu; Minhui Shen; Francis D Gibbons; Michelle L Lamb; Xiaolan Zheng; Richard M Stone; Daniel J Deangelo; Leonidas C Platanias; Les A Dakin; Huawei Chen; Paul D Lyne; Dennis Huszar
Journal:  Blood       Date:  2013-12-20       Impact factor: 22.113

5.  Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.

Authors:  Tadayuki Akagi; Lee-Yung Shih; Motohiro Kato; Norihiko Kawamata; Go Yamamoto; Masashi Sanada; Ryoko Okamoto; Carl W Miller; Der-Cherng Liang; Seishi Ogawa; H Phillip Koeffler
Journal:  Blood       Date:  2008-12-23       Impact factor: 22.113

6.  Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells.

Authors:  Zanna Beharry; Marina Zemskova; Sandeep Mahajan; Fengxue Zhang; Jian Ma; Zuping Xia; Michael Lilly; Charles D Smith; Andrew S Kraft
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

7.  Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model.

Authors:  Li Li; Obdulio Piloto; Ho Bao Nguyen; Kathleen Greenberg; Kogo Takamiya; Frederick Racke; David Huso; Donald Small
Journal:  Blood       Date:  2008-02-01       Impact factor: 22.113

8.  Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype.

Authors:  T A Müller; R Grundler; R Istvanffy; M Rudelius; L Hennighausen; A L Illert; J Duyster
Journal:  Leukemia       Date:  2016-04-05       Impact factor: 11.528

9.  FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm.

Authors:  S Haihua Chu; Diane Heiser; Li Li; Ian Kaplan; Michael Collector; David Huso; Saul J Sharkis; Curt Civin; Don Small
Journal:  Cell Stem Cell       Date:  2012-09-07       Impact factor: 24.633

10.  SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells.

Authors:  Ling Li; Tereza Osdal; Yinwei Ho; Sookhee Chun; Tinisha McDonald; Puneet Agarwal; Allen Lin; Su Chu; Jing Qi; Liang Li; Yao-Te Hsieh; Cedric Dos Santos; Hongfeng Yuan; Trung-Quang Ha; Mihaela Popa; Randi Hovland; Øystein Bruserud; Bjørn Tore Gjertsen; Ya-Huei Kuo; Wenyong Chen; Sonia Lain; Emmet McCormack; Ravi Bhatia
Journal:  Cell Stem Cell       Date:  2014-10-02       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.